Catalyst Pharmaceuticals (CPRX) News Today $21.27 -0.19 (-0.89%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barclays PLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Barclays PLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 129.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 248,458 shares of the biopharmaceutical company's stock afterDecember 21 at 4:09 AM | marketbeat.comWellington Management Group LLP Makes New $1.19 Million Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Wellington Management Group LLP purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 59,584 shares of the biopharmacDecember 20 at 3:39 AM | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Increase in Short InterestCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 6,090,000 shares, an increase of 7.2% from the November 15th total of 5,680,000 shares. Based on an average trading volume of 957,100 shares, the days-to-cover ratio is presently 6.4 days.December 17, 2024 | marketbeat.comCatalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2024 | globenewswire.comState Street Corp Sells 347,968 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)State Street Corp lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,685,330 shares of the biDecember 16, 2024 | marketbeat.comCatalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gainsDecember 14, 2024 | marketwatch.comJane Street Group LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Jane Street Group LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 245.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,908 shares of the biopharmaceuticaDecember 14, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $1,096,500.00 in StockDecember 12, 2024 | insidertrades.comJanus Henderson Group PLC Has $7.16 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Janus Henderson Group PLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 83.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 360,191 shares of the biopharmDecember 10, 2024 | marketbeat.comCatalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable FutureDecember 9, 2024 | seekingalpha.comVerition Fund Management LLC Buys 43,447 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Verition Fund Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 180.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,502 shares of the biopharmaceutical company's stoDecember 8, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from BrokeragesCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year pDecember 7, 2024 | marketbeat.comWhy Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?December 6, 2024 | finance.yahoo.comBNP Paribas Financial Markets Increases Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)BNP Paribas Financial Markets boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 206.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,250 shares of the biopharmaceutical company's stockDecember 6, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $23.22 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Charles Schwab Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,167,743 shares of the biopharmaceutical company's stocDecember 6, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Reduced by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 21.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,057,390 shares oDecember 5, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest UpdateCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 5,680,000 shares, a decline of 5.5% from the October 31st total of 6,010,000 shares. Based on an average daily volume of 946,800 shares, the short-interest ratio is currently 6.0 days.December 3, 2024 | marketbeat.comWalleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Walleye Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 248,288 shares of the biopharmaceutical cDecember 2, 2024 | marketbeat.comMartingale Asset Management L P Buys New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Martingale Asset Management L P purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 87,077 shares of the biopharmaceutical companDecember 2, 2024 | marketbeat.comZacks Research Issues Negative Forecast for CPRX EarningsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical cDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Intech Investment Management LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 32,395 shares of the biopharmaceuDecember 1, 2024 | marketbeat.comGary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockNovember 30, 2024 | insidertrades.comGary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Gary Ingenito sold 12,000 shares of the firm's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.November 29, 2024 | marketbeat.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells 17,500 Shares of StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) Director Molly Harper sold 17,500 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.November 29, 2024 | marketbeat.comCapstone Investment Advisors LLC Takes $708,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Capstone Investment Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 35,607 shares of the biopharmaceuticalNovember 29, 2024 | marketbeat.comFORA Capital LLC Takes $516,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)FORA Capital LLC bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 25,933 shares of the biopharmaceutical company's stock, valued at approximately $51November 29, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. Common Stock (CPRX)November 27, 2024 | nasdaq.comCatalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ ListNovember 25, 2024 | markets.businessinsider.comCatalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ ListNovember 25, 2024 | globenewswire.comSegall Bryant & Hamill LLC Acquires Shares of 40,633 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Segall Bryant & Hamill LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,633 shares of the biopharmaceutical company's stNovember 25, 2024 | marketbeat.comPacer Advisors Inc. Has $55.74 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Pacer Advisors Inc. lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,804,013 shares of the biopharmaceuNovember 22, 2024 | marketbeat.comQuest Partners LLC Has $742,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Quest Partners LLC increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 36,146.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,334 shares of the biopharmacNovember 22, 2024 | marketbeat.comStephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight RecommendationNovember 19, 2024 | msn.comCatalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 19, 2024 | globenewswire.comCatalyst Pharmaceuticals initiated with an Overweight at StephensNovember 19, 2024 | markets.businessinsider.comGSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)GSA Capital Partners LLP bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 31,437 shares of the biopharmaceutical company's stock, valued at apNovember 19, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at StephensStephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday. They set an "overweight" rating and a $35.00 price target for the company.November 18, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Principal Financial Group Inc. cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 575,953 shares of the biopharmaceutical company's stoNovember 18, 2024 | marketbeat.comRoyce & Associates LP Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Royce & Associates LP decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,021,105 shares of the biopharmaceutical company's stock after selling 140,917November 15, 2024 | marketbeat.comCatalyst Pharmaceuticals Board Member Trades $11.51M In Company StockNovember 15, 2024 | benzinga.comCatalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting PointNovember 13, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkNovember 13, 2024 | globenewswire.comLos Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Los Angeles Capital Management LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 159.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,282 shares of the biopharmaceutical companyNovember 13, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by AnalystsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts thNovember 12, 2024 | marketbeat.comCWA Asset Management Group LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)CWA Asset Management Group LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 26,845 shares of the biopharmaceutical company's stock, valued atNovember 12, 2024 | marketbeat.comCatalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 11, 2024 | finance.yahoo.comCatalyst Pharmaceuticals price target raised to $36 from $30 at TruistNovember 11, 2024 | markets.businessinsider.comTruist Financial Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $36.00Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday.November 11, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio ManagementMeritage Portfolio Management grew its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 121.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,914 shareNovember 11, 2024 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)November 9, 2024 | markets.businessinsider.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Indicator called BOTH NVDA rallies (Ad)Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼1.130.60▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼65▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News ITCI News ROIV News ASND News RVMD News LNTH News LEGN News NUVL News BPMC News ELAN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
